Angela Mastronuzzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4506184/publications.pdf

Version: 2024-02-01

236925 254184 2,648 166 25 citations h-index papers

g-index 170 170 170 4182 docs citations times ranked citing authors all docs

43

#	Article	IF	CITATIONS
1	Pediatric onco-hematological home care during COVID-19 pandemic. Supportive Care in Cancer, 2022, 30, 999-1002.	2.2	1
2	$TCR\hat{l}\pm\hat{l}^2/CD19$ depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Advances, 2022, 6, 281-292.	5.2	22
3	Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol. Neuro-Oncology, 2022, 24, 467-479.	1.2	5
4	Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers. Diagnostics, 2022, 12, 173.	2.6	16
5	Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience. Diagnostics, 2022, 12, 372.	2.6	10
6	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. Cancers, 2022, 14, 1540.	3.7	11
7	Acute Hematological Toxicity during Cranio-Spinal Proton Therapy in Pediatric Brain Embryonal Tumors. Cancers, 2022, 14, 1653.	3.7	4
8	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro-Oncology, 2022, 24, 1150-1163.	1.2	31
9	The Fight Just Born—Neonatal Cancer: Rare Occurrence with a Favorable Outcome but Challenging Management. Cancers, 2022, 14, 2244.	3.7	О
10	CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies. Frontiers in Immunology, 2022, 13, .	4.8	9
11	HGG-09. MicroRNAs expression profile in Meningioma 1 (MN1) gene altered astroblastoma. Neuro-Oncology, 2022, 24, i61-i61.	1.2	O
12	HGG-46. Inter and Intra-tumor Heterogeneity of Pediatric-type Diffuse High-Grade Glioma Revealed by High-Dimensional Single-Cell Proteomics. Neuro-Oncology, 2022, 24, 171-171.	1.2	1
13	The Prognostic Role of the C-Reactive Protein and Serum Lactate Dehydrogenase in a Pediatric Series of Bone Ewing Sarcoma. Cancers, 2022, 14, 3064.	3.7	2
14	Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement. Cancers, 2022, 14, 3378.	3.7	22
15	Liquid Biopsy with Detection of NRASQ61K Mutation in Cerebrospinal Fluid: An Alternative Tool for the Diagnosis of Primary Pediatric Leptomeningeal Melanoma. Diagnostics, 2022, 12, 1609.	2.6	2
16	Pediatric low-grade gliomas: molecular characterization of patient-derived cellular models. Child's Nervous System, 2021, 37, 771-778.	1.1	3
17	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro-Oncology, 2021, 23, 848-857.	1.2	24
18	Downregulation of miRâ \in 326 and its host gene \hat{l}^2 â \in arrestin1 induces proâ \in survival activity of E2F1 and promotes medulloblastoma growth. Molecular Oncology, 2021, 15, 523-542.	4.6	8

#	Article	IF	Citations
19	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.7	27
20	Melanotic Neuroectodermal Tumor of Infancy (MNTI) and Pineal Anlage Tumor (PAT) Harbor A Medulloblastoma Signature by DNA Methylation Profiling. Cancers, 2021, 13, 706.	3.7	12
21	Expanding the spectrum of EWSR1â€PATZ1 rearranged CNS tumors: An infantile case with leptomeningeal dissemination. Brain Pathology, 2021, 31, e12934.	4.1	11
22	Congenital Craniofacial Plexiform Neurofibroma in Neurofibromatosis Type 1. Diagnostics, 2021, 11, 218.	2.6	3
23	Rhabdoid Tumor Predisposition Syndrome: From Clinical Suspicion to General Management. Frontiers in Oncology, 2021, 11, 586288.	2.8	20
24	Medulloblastoma Associated with Down Syndrome: From a Rare Event Leading to a Pathogenic Hypothesis. Diagnostics, 2021, 11, 254.	2.6	3
25	Editorial: Recent Advances in Pediatric Cancer Predisposition Syndromes. Frontiers in Pediatrics, 2021, 9, 661894.	1.9	1
26	The Multidimensional Assessment for Pediatric Patients in Radiotherapy (M.A.PRT) Tool for Customized Treatment Preparation: RADAR Project. Frontiers in Oncology, 2021, 11, 621690.	2.8	8
27	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. Diagnostics, 2021, 11, 481.	2.6	5
28	Intraoperative Ultrasound-Assisted Extent of Resection Assessment in Pediatric Neurosurgical Oncology. Frontiers in Oncology, 2021, 11, 660805.	2.8	10
29	Molecular Characterization of Medulloblastoma in a Patient with Neurofibromatosis Type 1: Case Report and Literature Review. Diagnostics, 2021, 11, 647.	2.6	4
30	Expansion of the clinical and molecular spectrum of an <scp>XPD</scp> â€related disorder linked to biallelic mutations in <scp><i>ERCC2</i></scp> gene. Clinical Genetics, 2021, 99, 842-848.	2.0	4
31	Infantile Brain Tumors: A Review of Literature and Future Perspectives. Diagnostics, 2021, 11, 670.	2.6	4
32	Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas., 2021, 9, e001930.		21
33	Infra-Occipital Supra-Tentorial Approach for Resection of Low-Grade Tumor of the Left Lingual Gyrus: 2-Dimensional Operative Video. Operative Neurosurgery, 2021, 21, E257-E258.	0.8	4
34	Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma. Reports, 2021, 4, 12.	0.5	2
35	Synchronous Presentation of Rare Brain Tumors in Von Hippel–Lindau Syndrome. Diagnostics, 2021, 11, 1005.	2.6	2
36	Rosette-Forming Glioneuronal Tumor of the Fourth Ventricle: A Case of Relapse Treated with Proton Beam Therapy. Diagnostics, 2021, 11, 903.	2.6	1

#	Article	IF	CITATIONS
37	Magnetic Resonance Imaging during Proton Therapy Irradiation Allows for the Early Response Assessment of Pediatric Chordoma. Diagnostics, 2021, 11, 1117.	2.6	0
38	Tumor cell invasion into Matrigel: optimized protocol for RNA extraction. BioTechniques, 2021, 70, 327-335.	1.8	0
39	HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA. Neuro-Oncology, 2021, 23, i18-i18.	1.2	0
40	A pediatric COVID hematology/oncology ward to guarantee adequate medical and nursing assistance. Pediatric Blood and Cancer, 2021, 68, e29113.	1.5	5
41	Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. Frontiers in Immunology, 2021, 12, 634031.	4.8	2
42	TMOD-05. GENOME-WIDE DNA METHYLATION PROFILE: A POWERFUL STRATEGY TO RECAPITULATE HETEROGENEITY OF PEDIATRIC BRAIN TUMORS IN PRIMARY CELL LINES. Neuro-Oncology, 2021, 23, i36-i36.	1.2	0
43	GATA2 and marrow failure. Best Practice and Research in Clinical Haematology, 2021, 34, 101278.	1.7	8
44	<i>ALK</i> à€rearranged histiocytosis: Report of two cases with involvement of the central nervous system. Neuropathology and Applied Neurobiology, 2021, 47, 878-881.	3.2	9
45	Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript. Children, 2021, 8, 505.	1.5	4
46	Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. Acta Neuropathologica, 2021, 142, 537-564.	7.7	21
47	Peripheral Nervous System Involvement in Non-Primary Pediatric Cancer: From Neurotoxicity to Possible Etiologies. Journal of Clinical Medicine, 2021, 10, 3016.	2.4	4
48	The 4YouLab Model: A Dedicated-Program for Adolescents and Young Adults With Cancer in a Children's Hospital. Frontiers in Oncology, 2021, 11, 705419.	2.8	0
49	Intradural Pediatric Spinal Tumors: An Overview from Imaging to Novel Molecular Findings. Diagnostics, 2021, 11, 1710.	2.6	12
50	Pediatric Extraspinal Sacrococcygeal Ependymoma: Report of Two Cases and Literature Review. Diagnostics, 2021, 11, 1680.	2.6	1
51	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. International Journal of Molecular Sciences, 2021, 22, 642.	4.1	12
52	Upfront treatment with <scp>mTOR</scp> inhibitor everolimus in pediatric lowâ€grade gliomas: A singleâ€enter experience. International Journal of Cancer, 2021, 148, 2522-2534.	5.1	19
53	Cognitive deficits in childrens with brain tumours: A project to create a software for cognitive training. Journal of the Neurological Sciences, 2021, 429, 118451.	0.6	0
54	Cerebrospinal Fluid Levels of AFP and hCG: Validation of the Analytical Method and Application in the Diagnosis of Central Nervous System Germ Cell Tumors. Diagnostics, 2021, 11, 1980.	2.6	1

#	Article	IF	CITATIONS
55	An atypical presentation of diffuse midline pontine glioma in a middle age patient: Case report. Journal of Clinical Neuroscience, 2020, 71, 293-295.	1.5	0
56	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. Acta Neuropathologica, 2020, 139, 583-596.	7.7	13
57	Integration of Multiple Platforms for the Analysis of Multifluorescent Marking Technology Applied to Pediatric GBM and DIPG. International Journal of Molecular Sciences, 2020, 21, 6763.	4.1	9
58	Early Onset Epilepsy Caused by Low-Grade Epilepsy-Associated Tumors and Focal Meningeal Involvement. Brain Sciences, 2020, 10, 752.	2.3	1
59	Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas. Frontiers in Pediatrics, 2020, 8, 561487.	1.9	8
60	The Management of Children with Cancer during the COVID-19 Pandemic: A Rapid Review. Journal of Clinical Medicine, 2020, 9, 3756.	2.4	11
61	A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. Frontiers in Oncology, 2020, 10, 1228.	2.8	10
62	Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era. Frontiers in Oncology, 2020, 10, 566822.	2.8	17
63	GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes. Cancers, 2020, 12, 2962.	3.7	16
64	Infantile/Congenital High-Grade Gliomas: Molecular Features and Therapeutic Perspectives. Diagnostics, 2020, 10, 648.	2.6	15
65	Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. Cancers, 2020, 12, 2684.	3.7	30
66	Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. Diagnostics, 2020, 10, 582.	2.6	21
67	IMG-19. RADIOMICS AND SUPERVISED DEEP LEARNING TO PREDICT MOLECULAR SUBGROUPS IN MEDULLOBLASTOMA BASED ON WHOLE TUMOR VOLUME LABELING: A SINGLE CENTER MULTIPARAMETRIC MR ANALYSIS. Neuro-Oncology, 2020, 22, iii358-iii359.	1.2	O
68	Ectopic ACTH Secretion in a Child With Metastatic Ewing's Sarcoma: A Case Report. Frontiers in Oncology, 2020, 10, 574.	2.8	3
69	Central nervous system high-grade neuroepithelial tumor with BCOR alteration (CNS) Tj ETQq1 1 0.784314 rgBT	/Qverlock	10 Tf 50 18
70	Editorial: Pediatric Central Nervous System Tumors: State-of-the-Art and Debated Aspects. Frontiers in Pediatrics, 2020, 8, 91.	1.9	0
71	Delayed referral of pediatric brain tumors during COVID-19 pandemic. Neuro-Oncology, 2020, 22, 1884-1886.	1.2	22
72	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	9.4	157

#	Article	IF	CITATIONS
73	DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk. Frontiers in Oncology, 2020, 10, 614541.	2.8	30
74	Modeling medulloblastoma in vivo and with human cerebellar organoids. Nature Communications, 2020, 11, 583.	12.8	105
7 5	IMG-14. DEVELOPING A PREDICTIVE GRADING MODEL FOR CHILDREN WITH GLIOMAS BASED ON DIFFUSION KURTOSIS IMAGING METRICS: ACCURACY AND CLINICAL CORRELATIONS WITH SURVIVAL. Neuro-Oncology, 2020, 22, iii357-iii358.	1.2	0
76	MODL-23. DNA METHYLATION AND COPY NUMBER VARIATION PROFILE FOR CHARACTERIZATION OF PEDIATRIC BRAIN TUMOR PRIMARY CELL LINES. Neuro-Oncology, 2020, 22, iii415-iii415.	1.2	0
77	HGG-19. IDENTIFICATION OF NOVEL SUBGROUP-SPECIFIC miRNA EXOSOMAL BIOMARKERS IN PEDIATRIC HIGH-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii347-iii347.	1.2	0
78	MBCL-18. ANALYSIS OF DNA METHYLATION PROFILES OF PEDIATRIC MEDULLOBLASTOMAS: EXPERIENCE AT THE BAMBINO GESÙ CHILDREN'S HOSPITAL. Neuro-Oncology, 2020, 22, iii391-iii392.	1.2	0
79	IMG-16. WHOLE TUMOR DIFFUSION KURTOSIS IMAGING ANALYSIS FOR DISCRIMINATING PEDIATRIC POSTERIOR FOSSA TUMORS: ACCURACY AND REPEATABILITY. Neuro-Oncology, 2020, 22, iii358-iii358.	1.2	0
80	SURG-03. IMMERSIVE VIRTUAL REALITY APPLICATIONS IN NEUROSURGICAL ONCOLOGY. Neuro-Oncology, 2020, 22, iii461-iii461.	1.2	0
81	IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2020, 22, iii362-iii362.	1.2	0
82	HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG. Neuro-Oncology, 2020, 22, iii346-iii346.	1.2	0
83	LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT. Neuro-Oncology, 2020, 22, iii369-iii369.	1.2	2
84	EPEN-03. LONG-TERM FOLLOW-UP OF AIEOP 2ND SERIES OF CHILDREN AND ADOLESCENT WITH PRIMARY INTRACRANIAL (ST:SUPRATENTORIAL; PF: POSTERIOR FOSSA) EPENDYMOMA AND METHYLATION GROUPS RE-ANALYSES. Neuro-Oncology, 2020, 22, iii308-iii308.	1.2	0
85	NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE. Neuro-Oncology, 2020, 22, iii419-iii419.	1.2	0
86	PATH-19. MOLECULAR CLASSIFICATION BASED ON THE DNA METHYLATION PROFILE OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN CHILDREN: TWO-YEARS EXPERIENCE AT THE BAMBINO GESÙ HOSPITAL. Neuro-Oncology, 2020, 22, iii428-iii428.	1.2	0
87	MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS. Neuro-Oncology, 2020, 22, iii408-iii408.	1.2	0
88	HGG-54. HISTOLOGICAL AND MOLECULAR CHARACTERIZATION OF HIGH-GRADE BRAIN TUMORS SECONDARY TO TOTAL BODY IRRADIATION FOR HEMATOLOGICAL MALIGNANCIES. Neuro-Oncology, 2020, 22, iii353-iii354.	1.2	0
89	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. Neuro-Oncology, 2019, 21, ii123-ii124.	1.2	0
90	Role of DNA Methylation Profile in Diagnosing Astroblastoma: A Case Report and Literature Review. Frontiers in Genetics, 2019, 10, 391.	2.3	25

#	Article	IF	CITATIONS
91	IMMU-12. NOVEL APPROACH FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMAS WITH THE COMBINATION OF ONCOLYTIC ADENOVIRUSES AND GENE THERAPY ENCODING A BITE DIRECTED TO THE EphA2 TUMOR ANTIGEN Neuro-Oncology, 2019, 21, ii95-ii95.	1.2	0
92	Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project. Pediatric Blood and Cancer, 2019, 66, e27749.	1.5	1
93	Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome. Frontiers in Oncology, 2019, 9, 277.	2.8	10
94	Direct Involvement of Cranial Nerve V at Diagnosis in Patients With Diffuse Intrinsic Pontine Glioma: A Potential Magnetic Resonance Predictor of Short-Term Survival. Frontiers in Oncology, 2019, 9, 204.	2.8	4
95	Propofol-based palliative sedation in terminally ill children with solid tumors. Medicine (United) Tj ETQq1 1 0.7843	14.rgBT /0	Oyerlock 10
96	Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel <i>KMT2D</i> mutation. American Journal of Medical Genetics, Part A, 2019, 179, 113-117.	1.2	10
97	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	2.9	30
98	Foxm1 controls a pro-stemness microRNA network in neural stem cells. Scientific Reports, 2018, 8, 3523.	3.3	40
99	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1–TGF-β–OTX2–SNAIL via PTEN inhibition. Brain, 2018, 141, 1300-1319.	7.6	22
100	Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. Cancer Research, 2018, 78, 3337-3349.	0.9	64
101	NSRG-18. IMPACT OF MOLECULAR SUBGROUP ON SURGICAL MANAGEMENT OF MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i149-i149.	1.2	O
102	QOL-35. EXPRESSIVE WRITING FOR ADOLESCENTS WITH BRAIN TUMOR: A CASE STUDY. Neuro-Oncology, 2018, 20, i164-i164.	1.2	1
103	HGG-23. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2018, 20, i93-i94.	1.2	1
104	EPEN-03. PEDIATRIC INTRACRANIAL EPENDYMOMA: CORRELATION OF SYMPTOMS AND SIGNS AT RECURRENCE WITH OUTCOME IN THE SECOND PROSPECTIVE AIEOP PROTOCOL FOLLOW-UP. Neuro-Oncology, 2018, 20, i73-i74.	1.2	0
105	PDTM-09. DIFFUSE INTRINSIC PONTINE GLIOMA AND PEDIATRIC GLIOBLASTOMA DERIVED-EXOSOMES HAVE SPECIFIC ONCOGENIC SIGNATURES. Neuro-Oncology, 2018, 20, vi205-vi205.	1.2	1
106	RADI-18. DIFFUSION KURTOSIS IMAGING CAN HELP DIFFERENTIATE LOW- AND HIGH-GRADE GLIOMAS IN PEDIATRIC PATIENTS: A PROSPECTIVE SINGLE CENTRE STUDY. Neuro-Oncology, 2018, 20, i173-i173.	1.2	0
107	PDTM-31. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. Neuro-Oncology, 2018, 20, vi210-vi210.	1.2	O
108	Numb Isoforms Deregulation in Medulloblastoma and Role of p66 Isoform in Cancer and Neural Stem Cells. Frontiers in Pediatrics, 2018, 6, 315.	1.9	10

#	Article	IF	Citations
109	BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas. Frontiers in Oncology, 2018, 8, 526.	2.8	37
110	MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877537.	3.5	28
111	RADI-19. DIFFUSION KURTOSIS IMAGING CAN HELP DIFFERENTIATE LOW- AND HIGH-GRADE GLIOMAS IN PEDIATRIC PATIENTS WITH SPECIFIC LOCATION-RELATED PATTERNS: A PROSPECTIVE SINGLE CENTRE STUDY. Neuro-Oncology, 2018, 20, i173-i174.	1.2	0
112	Congenital Extra-Ventricular (Ganglio) Neurocytoma of the Brain Stem: A Case Report. Frontiers in Pediatrics, 2018, 6, 108.	1.9	4
113	Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease. Pediatric Radiology, 2018, 48, 1724-1735.	2.0	2
114	Congenital Rhabdomyosarcoma: a different clinical presentation in two cases. BMC Pediatrics, 2018, 18, 166.	1.7	12
115	Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up. Journal of Neuro-Oncology, 2018, 140, 457-465.	2.9	7
116	Robot-Assisted Stereotactic Biopsy of Diffuse Intrinsic Pontine Glioma: A Single-Center Experience. World Neurosurgery, 2017, 101, 584-588.	1.3	50
117	Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. Pediatric Neurology, 2017, 68, 59-63.	2.1	15
118	Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature. Pediatric Radiology, 2017, 47, 633-648.	2.0	20
119	Growth hormone excess in children with neurofibromatosis type†and optic glioma. American Journal of Medical Genetics, Part A, 2017, 173, 2353-2358.	1.2	38
120	\hat{l}^2 -arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. BMC Cancer, 2017, 17, 488.	2.6	62
121	Intraspinal Mesenchymal Chondrosarcoma: Report of a Pediatric Case and Literature Review. Tumori, 2017, 103, S66-S72.	1.1	4
122	Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs). International Journal of Molecular Sciences, 2017, 18, 2742.	4.1	19
123	Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 1328-1343.	1.7	5
124	The long noncoding RNA linc-NeD125 controls the expression of medulloblastoma driver genes by microRNA sponge activity. Oncotarget, 2017, 8, 31003-31015.	1.8	56
125	MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs. Stem Cells International, 2016, 2016, 1-10.	2.5	8
126	Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications. Stem Cells International, 2016, 2016, 1-11.	2.5	24

#	Article	IF	CITATIONS
127	Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor. Pediatric Blood and Cancer, 2016, 63, 719-722.	1.5	7
128	Anomalous vascularization in a Wnt medulloblastoma: a case report. BMC Neurology, 2016, 16, 103.	1.8	9
129	NRASQ61K mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications. BMC Cancer, 2016, 16, 512.	2.6	16
130	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-Oncology, 2016, 18, 1451-1460.	1.2	108
131	Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma. BMC Pediatrics, 2016, 16, 99.	1.7	6
132	Fungal infections of the lung in children. Pediatric Radiology, 2016, 46, 1856-1865.	2.0	16
133	Pediatric spinal glioblastoma of the conus medullaris: a case report of long survival. Chinese Journal of Cancer, 2016, 35, 44.	4.9	11
134	IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. Oncotarget, 2016, 7, 52900-52911.	1.8	34
135	Abstract 970: Circulating microRNA signature in group 4 medulloblastoma patients., 2016,,.		0
136	Spinal ependymoma in a patient with Kabuki syndrome: a case report. BMC Medical Genetics, 2015, 16, 80.	2.1	23
137	Sporadic Retinoblastoma and Pilocytic Astrocytoma: A Rare Association of Two Tumors. Pediatric Blood and Cancer, 2015, 62, 2245-2246.	1.5	2
138	Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 603-607.	2.8	19
139	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Biomarker Research, 2015, 3, 13.	6.8	28
140	Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. Journal of Translational Medicine, 2014, 12, 356.	4.4	79
141	Behavioral disorders as unusual presentation of pediatric extraventricular neurocytoma: report on two cases and review of the literature. BMC Neurology, 2014, 14, 242.	1.8	10
142	Wernicke Encephalopathy in Pediatric Neuro-oncology. Journal of Child Neurology, 2014, 29, NP181-NP185.	1.4	14
143	Congenital cystic eye associated with a low-grade cerebellar lesion that spontaneously regressed. BMC Ophthalmology, 2014, 14, 80.	1.4	3
144	Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features. BMC Cancer, 2014, 14, 262.	2.6	14

#	Article	IF	CITATIONS
145	Peripheral medulloepithelioma: a rare tumor with a potential target therapy. Journal of Translational Medicine, 2014, 12, 49.	4.4	7
146	Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica, 2014, 99, e127-e129.	3.5	26
147	Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, 2014, 5, 2052-2064.	1.8	92
148	ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas. BMC Cancer, 2013, 13, 255.	2.6	19
149	Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option. Anticancer Research, 2013, 33, 3515-8.	1.1	6
150	Unmanipulated Donor Lymphocytes for EBV-Related PTLD After T-Cell Depleted HLA-Haploidentical Transplantation. Pediatrics, 2012, 129, e189-e194.	2.1	12
151	Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy. International Journal of Oncology, 2012, 41, 117-24.	3.3	4
152	Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood, 2012, 120, 473-476.	1.4	170
153	Monitoring of Human Cytomegalovirus and Virus-Specific T-Cell Response in Young Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2012, 7, e41648.	2.5	53
154	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group Blood, 2012, 120, 2494-2494.	1.4	0
155	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 339-349.	1.7	17
156	OUTCOME of Unrelated DONOR BONE MARROW TRANSPLANTATION for THALASSEMIA MAJOR PATIENTS. Blood, 2011, 118, 149-149.	1.4	4
157	Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients. Experimental Hematology, 2010, 38, 426-433.	0.4	32
158	The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation. Annals of the New York Academy of Sciences, 2010, 1202, 141-148.	3.8	17
159	The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia. Bone Marrow Transplantation, 2010, 45, 1618-1624.	2.4	21
160	The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachmanâ€Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. British Journal of Haematology, 2009, 145, 190-197.	2.5	60
161	Germâ€ine mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. British Journal of Haematology, 2009, 147, 706-709.	2.5	46
162	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. British Journal of Haematology, 2008, 143, 548-551.	2.5	60

#	Article	IF	CITATIONS
163	Donor/recipient mixed chimerism does not predict graft failure in children with Â-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica, 2008, 93, 1859-1867.	3.5	68
164	Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience. Frontiers in Surgery, 0, 9, .	1.4	2
165	GATA 2 Deficiency: Focus on Immune System Impairment. Frontiers in Immunology, 0, 13, .	4.8	5
166	Posterior fossa ependymoma in neurodevelopmental syndrome caused by a de novo germline pathogenic <i>Polr2a</i> variant. American Journal of Medical Genetics, Part A, O, , .	1.2	2